Regulator seems ready to approve a vaccine with lower efficacy rates. Will it be right giving some people lower chances of being protected?
Vaccines are like buses. You wait for one for ages, then they all come trundling along together, by which time a whole crowd is clamouring to get on board.
But what if a cheaper, less reliable bus arrives during the melee. Would you get on it, or wait for space on the dependable, newer model?
Herein lies the dilemma of the Oxford/AstraZeneca vaccine. It now seems likely that regulators will only approve a two-dose regime, with an efficacy rate of around 62 per cent, far less than the 95 per cent promised by Pfizer and Moderna.
Experts have already warned this could leave large proportions of the population vaccinated, but unprotected.